U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

					s are required to respon	10.0			it displays a valid OMB control nu	\
Substitute for form 1449/PTO						Complete if known				\rightarrow
INFORMATION DISCLOSURE							Application Number 10/559,814 Filing Date April 4, 2006			
STATEMENT BY APPLICANT (Use as many sheets as necessary)						Fir	First Named Inventor Mark B. Pepys			
						Ar	Unit	1646 1646		
` '							aminer Name	Net-Yet-Assigned KULXLANC		
Sheet of			1	Att	Attorney Docket Number		068800-0324485			
					U.S. PATENT	DOC	CUMENTS			
Examiner Initials*	Cite	Document Number			Publication Date	,	Name of Patentee or		Pages, Columns, Lines, where	
	No.1	Number-Kind Code ² (if known)			MM-DD-YYYY		Applicant of Cited Documer		nt Relevant Passages or Relevant Figures Appear	
	AA	US-								
	AB	US-						İ		
	AC	US-							The second secon	
	AD	US-								
	AE	US-					<u> </u>		* **** * * * **************************	
	AF	US-	*	7	· · · · · · · · · · · · · · · · · · ·					
	AG	US-	•							
	AH	US-			, , ,	1				
					FOREIGN PATEN	NT D	OCUMENTS			
Examiner Initials*	Cite	Foreign Patent Document			Publication Date	1	Name of Patentee or		Pages, Columns, Lines, where Relevant Passages or Relevant T ⁶ Figures Appear	
	No. ¹		ry Code³-Ni Code⁵ (if k		MM-DD-YYYY		Applicant of Cited Docume			
	AI									
	AJ									
	AK					_				
	AL									
	AM	L								با

NON PATENT LITERATURE DOCUMENTS									
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶						
	AN	Nishukaku et. al., "Protective Effects of D-Penicillamine and a Thiazole Derivative, SM-8849, on Pristane-Induced Arthritis in Mice," International Journal of Immunopharmacology, vol. 16, no 2 pp 91-100, 1994.							
	AO	Danielsen et. al., "Calcium-dependent and -independent binding of the pentraxin serum amyloid P component to glycosaminoglycans and amyloid proteins: enhanced binding at slightly acid pH," Biochimica et Biophysica Acta 1339 (1997) 73-78							
	AP								
	AQ								
	AR								

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

/Ruixiang Li/

Examiner Signature

Date Considered

09/22/2009